Im vergangenen Jahr erzielte Alkermes Plc für sein leistungsstärkstes Segment, VIVITROL, Einnahmen von 467.91M USD. Die Region United States leistete den größten Beitrag mit 1.37B USD im letzten Jahr.

Nach Geschäftsbereich

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

VIVITROL

ARISTADA

LYBALVI

Royalty Revenue - VUMERITY

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

Royalty-Other

Manufacturing-RISPERDAL CONSTA

Manufacturing Revenue - VUMERITY

Manufacturing-Other

Royalty-RISPERDAL CONSTA

Manufacturing-AMPYRA/FAMPYRA

Royalty-AMPYRA/FAMPYRA

Manufacturing-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

VIVITROL

467.91M(31.70%)

457.31M(29.36%)

400.42M(24.07%)

379.48M(34.20%)

343.85M(29.62%)

310.72M(30.00%)

335.37M(34.49%)

ARISTADA

370.04M(25.07%)

346.19M(22.23%)

327.69M(19.70%)

302.05M(27.22%)

275.36M(23.72%)

241.04M(23.27%)

189.13M(19.45%)

LYBALVI

346.69M(23.49%)

280.03M(17.98%)

191.89M(11.54%)

96.02M(8.65%)

--(--)

Royalty Revenue - VUMERITY

113.93M(7.72%)

94.75M(6.08%)

86.44M(5.20%)

83.00M(7.48%)

61.61M(5.31%)

--(--)

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

109.57M(7.42%)

236.39M(15.18%)

486.10M(29.22%)

115.66M(10.42%)

303.11M(26.11%)

274.20M(26.47%)

256.95M(26.42%)

Royalty-Other

21.70M(1.47%)

23.26M(1.49%)

27.20M(1.63%)

13.71M(1.24%)

40.52M(3.49%)

55.31M(5.34%)

55.56M(5.71%)

Manufacturing-RISPERDAL CONSTA

19.57M(1.33%)

23.17M(1.49%)

36.12M(2.17%)

42.67M(3.85%)

40.41M(3.48%)

56.89M(5.49%)

50.43M(5.19%)

Manufacturing Revenue - VUMERITY

16.54M(1.12%)

39.29M(2.52%)

42.89M(2.58%)

32.49M(2.93%)

25.81M(2.22%)

--(--)

Manufacturing-Other

9.89M(0.67%)

56.96M(3.66%)

63.49M(3.82%)

37.21M(3.35%)

12.00M(1.03%)

35.23M(3.40%)

31.75M(3.27%)

Royalty-RISPERDAL CONSTA

55.00K(--)

272.00K(0.02%)

1.15M(0.07%)

7.24M(0.65%)

10.46M(0.90%)

14.47M(1.40%)

15.95M(1.64%)

Manufacturing-AMPYRA/FAMPYRA

--(--)

27.41M(2.36%)

26.91M(2.60%)

22.07M(2.27%)

Royalty-AMPYRA/FAMPYRA

--(--)

20.48M(1.76%)

20.98M(2.03%)

15.17M(1.56%)

Manufacturing-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

--(--)

Nach Region

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

United States

Rest of the World

Ireland

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

1.37B(93.01%)

1.41B(90.53%)

1.49B(89.69%)

931.99M(83.83%)

984.24M(83.85%)

839.00M(80.77%)

966.93M(82.58%)

Rest of the World

102.36M(6.94%)

146.18M(9.38%)

170.29M(10.24%)

177.97M(16.01%)

187.34M(15.96%)

196.53M(18.92%)

200.82M(17.15%)

Ireland

754.00K(0.05%)

1.29M(0.08%)

1.18M(0.07%)

1.83M(0.16%)

2.17M(0.19%)

3.23M(0.31%)

3.19M(0.27%)